Krazati Associated With Superior Outcomes Than Docetaxel in KRAS G12C+ NSCLC
Among patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), treatment via Krazati (adagrasib) was associated with superior outcomes when compared to treatment with docetaxel (DOCE), regardless of whether those patients had baseline brain metastases, according to findings from the […]
Krazati Associated With Superior Outcomes Than Docetaxel in KRAS G12C+ NSCLC Read More »